|
KMID : 0369820050350010057
|
|
Jorunal of Korean Pharmaceutical Sciences
2005 Volume.35 No. 1 p.57 ~ p.63
|
|
|
Stereochemical Issues in Chiral Drug Development
|
|
최선옥/Choi SO
정성희/엄소영/정서정/김주일/정수연/Jung SH/Um SY/Jung SJ/Kim JI/Chung SY
|
|
|
Abstract
|
|
|
|
Numerous drugs are chiral because they possess one or more chiral centers. Enantiomers may differ in their pharmacokinetic, pharmacological and toxicological properties. However, the significance of stereochemistry of drugs in their therapeutic uses has received relatively little attention until recently. The US FDA issued a guideline on stereoisomeric drugs in 1992, and the European agency describes tests for new drug substances which are optically active in an ICH(International Conference of Harmonization) guideline. According to the guidance, enantiomers may differ in their pharmacokinetic, pharmacological and toxicological properties. Therefore, in this paper, we examined the recently published Canadian guidance, stereochemical issues in chiral drug development, which will be references to make a guidance on stereochemical issues in chiral drug development in Korea.
|
|
|
KEYWORD
|
|
|
Chiral, Enantiomer, Stereochemistry
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|